Blinatumomab Injection for Pediatric ALL Treatment

This contract is for the procurement of a medication containing the active ingredient blinatumomab, specifically a powder for infusion concentrate. Each vial contains 38.5 micrograms of blinatumomab, which, when reconstituted with sterile water, results in a final concentration of 12.5 micrograms/ml. The medication is indicated for use as a monotherapy in pediatric patients aged 1 month or older for the treatment of acute lymphoblastic leukemia (ALL) originating from precursor B-cells that are Philadelphia chromosome-negative and CD19-positive. It is intended for patients who are refractory or have relapsed after at least two prior treatments or have relapsed following a previous allogeneic stem cell transplant. Additionally, it is indicated for high-risk patients in their first relapse as part of consolidation therapy. The total contract value is €165,611.20, and the deadline for submissions is July 23, 2025. For more details, please visit the contract platform at TED.